Sacubitril/valsartan (ARNI), a medication that combines an angiotensin receptor blocker and a neprilysin inhibitor, demonstrated superior efficacy compared to ACE inhibitors in lowering the risks of death and hospitalization due to HF [89]. This evidence concerns the gene ACE and hydrops fetalis.